Clinical trials: Solid Tumor in Children, active
Solid Tumors, Hematological Tumor
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
The goal of this clinical trial is to evaluate the efficacy and safety of romiplostim N01 in treating chemotherapy-induced thrombocytopenia (CIT) in children and adolescents/young adults (CAYA; aged 6-24 years) with hematologic…
- Conditions
- Solid Tumors, Hematological Tumor, Children, Adolescent
- Trial name
- NCT07043894
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Recurrent Solid Tumor, Recurrent Ewing Sarcoma
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away).
- Conditions
- Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor
- Trial name
- NCT04901702
- Testing
- Onivyde, Talazoparib, Temozolomide
- Where
- 10 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- St. Jude Children's Research Hospital
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Solid Tumors, Relapsed Solid Tumors
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B).
- Conditions
- Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma
- Trial name
- PEEL-224 (NCT06721689)
- Testing
- PEEL-224, Vincristine, Temozolomide (TMZ)
- Where
- 7 sites in United States
- Volunteers
- 59 people
- Sponsor
- Theodore Laetsch
Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
This is a prospective, single-center, single-arm interventional trial conducted at Tianjin Medical University Cancer Institute and Hospital.
- Trial name
- NCT07444918
- Testing
- Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs)
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China.
- Conditions
- Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
- Trial name
- NCT06873672
- Where
- China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Solid Tumor, Central Nervous System Tumor
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
- Conditions
- Solid Tumor, Central Nervous System Tumor, Lymphoma, Leukemia
- Trial name
- NCT02932280
- Testing
- Neratinib
- Where
- 9 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors, Children
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
The goal of this clinical trial is to evaluate the efficacy and safety of Telpegfilgrastim (a PEGylated recombinant human granulocyte colony-stimulating factor, PEG-rhG-CSF) compared to Filgrastim (short-acting rhG-CSF) in…
- Conditions
- Solid Tumors, Children, Adolescent, Chemotherapy Induced Neutropenia
- Trial name
- NCT06926751
- Testing
- Telpegfilgrastim Injection, filgrastim
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
CNS Tumor, Solid Tumor
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
The aim of this trial is to determine preliminary activity of the combination treatment with nivolumab and entinostat in children and adolescents with high risk refractory/relapsed/progressive tumors harboring a high mutational…
- Trial name
- NCT03838042
- Testing
- Nivolumab and Entinostat
- Where
- 14 sites in Australia, Austria and 5 more
- Volunteers
- 91 people
- Sponsor
- University Hospital Heidelberg
Solid Tumor
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of…
- Trial name
- AflacST1903 (NCT04469530)
- Testing
- Sirolimus, Cyclophosphamide, Etoposide
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Emory University
Solid Tumor, Childhood, Brain Tumor, Pediatric
Social Emotional Development in Young Children With Cancer
Many children with cancer are diagnosed in early childhood, and as such, will likely miss key social experiences such as participation in preschool or kindergarten, playing on playgrounds, and other normative experiences.
- Trial name
- NCT03086421
- Testing
- Questionnaires
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- St. Jude Children's Research Hospital
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Solid Tumour
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation.
- Trial name
- DETERMINE (NCT05722886)
- Testing
- Alectinib, Atezolizumab, Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 825 people
- Sponsor
- Cancer Research UK
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Vincristine Pharmacokinetics in Infants
This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children.
- Trial name
- NCT05359237
- Testing
- Biospecimen Collection, Vincristine
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 83 people
- Sponsor
- Children's Oncology Group
Adrenal Gland Pheochromocytoma, Carcinoma In Situ
Project: Every Child for Younger Patients With Cancer
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and…
- Conditions
- Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma
- Trial name
- NCT02402244
- Testing
- Cytology Specimen Collection Procedure, Medical Chart Review
- Where
- 279 sites in United States, Australia and 4 more
- Volunteers
- 75,000 people
- Sponsor
- Children's Oncology Group
Neuroblastoma, Sarcoma
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3…
- Conditions
- Neuroblastoma, Sarcoma, Osteosarcoma
- Trial name
- NCT06500819
- Testing
- B7-H3CART Dose (Intravenous)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanford University
Liver Cancer, Rhabdomyosarcoma
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment.
- Conditions
- Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma
- Trial name
- NCT04377932
- Testing
- AGAR T cells
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Baylor College of Medicine